BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, February 6, 2025
See today's BioWorld
Home
» Neuren’s NNZ-2591 meets endpoints in phase II trial in Phelan-McDermid syndrome
To read the full story,
subscribe
or
sign in
.
Neuren’s NNZ-2591 meets endpoints in phase II trial in Phelan-McDermid syndrome
Dec. 18, 2023
By
Tamra Sami
No Comments
Neuren Pharmaceuticals Ltd. plans to progress NNZ-2591 to phase III trials following positive top-line phase II results in children with Phelan-McDermid syndrome, a genetic neurodevelopmental disorder for which there are no approved treatments.
BioWorld
Clinical
Neurology/psychiatric
Asia-Pacific
Australia